Tyrosine kinase inhibitors and interferon
Related Experiment Video
Updated: May 3, 2026

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Maria Dimou1, Panagiotis Panayiotidis1
11 Department of Propaedeutic Medicine, Division of Hematology, University of Athens, Greece.
Abstract:
The use of interferon-a (INF) in chronic myeloid leukemia, when it started in the 80s, was considered as a breakthrough in the therapy of this disease; INF administered alone or in combination with aracytin was the standard choice for treatment for Chronic Myeloid Leukemia (CML) patients unfit for bone marrow transplantation. With the appearance of the first Tyrosine Kinase Inhibitor (TKI) (imatinib) and based on the results of the pivotal IRIS trial, imatinib monotherapy was the new treatment of choice for CML, according to the ELN recommendations. The possibility of combining INF with imatinib, for obtaining better therapeutic responses in CML patients has been already tested and reported. The current challenge is the combined use of second generation TKIs with pegylated -IFN, in order to minimize failures to therapy and increase the number of CML patients with deep molecular responses, who may be able to discontinue lifelong treatment.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Receptor Tyrosine Kinases
Inhibition of Cdk Activity

